Published Date: 08 Mar 2023
This review compared the effectiveness of entecavir and tenofovir in reducing relapses and mortality after treatment for HBV-related hepatocellular carcinoma.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
2.
Do I qualify for a cancer clinical trial?
3.
Providing essential cancer care to rural communities
4.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
5.
novel approach to test the toxicity of cancer drugs.
1.
Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts
2.
Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
5.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation